Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues

Hormones and Cancer

Volumn 5, Issue 2, 2014, Pages 61-71

  Hu, Dong Gui ^a   Hickey, Theresa E ^b   Irvine, Connie ^b   Wijayakumara, Dhilushi Dodampege ^a   Lu, Lu ^a   Tilley, Wayne D ^b   Selth, Luke A ^b   Mackenzie, Peter I ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; ISOPROTEIN;

3' UNTRANSLATED REGION; ADIPOSE TISSUE; ALLELE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMPLICON; ARTICLE; BLADDER; BRAIN; BREAST; BREAST CANCER; CANCER CELL CULTURE; CLINICAL ARTICLE; CODON; COLON; ESOPHAGUS; EXON; FEMALE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HEART; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY; KIDNEY CELL; LIVER; LUNG; MALE; OVARY; PLACENTA; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE; SMALL INTESTINE; SPLEEN; TESTIS; THYMUS; THYROID GLAND; TRACHEA; UTERINE CERVIX; BREAST TUMOR; GENE EXPRESSION PROFILING; GENETICS; HEK293 CELL LINE; HEPG2 CELL LINE; MCF 7 CELL LINE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; EXONS; FEMALE; GENE EXPRESSION PROFILING; HEK293 CELLS; HEP G2 CELLS; HUMANS; MALE; MCF-7 CELLS; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; TRANSCRIPTION, GENETIC;

EID: 84897991381     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-014-0171-4     Document Type: Article

References (44)

1. Matsumoto T et al (2013) The androgen receptor in health and disease. Annu Rev Physiol 75: 201-224.
2. Chang C et al (2013) Androgen Receptor (AR) physiological roles in male and female reproductive systems: lessons learned from AR-knockout mice lacking AR in selective cells. Biol Reprod 89(1): 21.
3. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25(2): 276-308.
4. Fu W et al (2012) Progress of molecular targeted therapies for prostate cancers. Biochim Biophys Acta 1825(2): 140-152.
5. Scher HI et al (2004) Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11(3): 459-476.
6. Brand LJ, Dehm SM (2013) Androgen receptor gene rearrangements: new perspectives on prostate cancer progression. Curr Drug Targets 14(4): 441-449.
7. Gelmann EP (2002) Molecular biology of the androgen receptor. J Clin Oncol 20(13): 3001-3015.
8. Tilley WD et al (1989) Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci U S A 86(1): 327-331.
9. Dehm SM et al (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68(13): 5469-5477.
10. Hu R, Isaacs WB, Luo J (2011) A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71(15): 1656-1667.
11. Hu R et al (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69(1): 16-22.
12. Guo Z et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69(6): 2305-2313.
13. Ahrens-Fath I et al (2005) Androgen receptor function is modulated by the tissue-specific AR45 variant. FEBS J 272(1): 74-84.
14. Liu LL et al (2013) Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. doi: 10. 1038/onc. 2013. 284.
15. Li Y et al (2012) AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 31(45): 4759-4767.
16. Nyquist MD et al (2013) TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A 110(43): 17492-17497.
17. Sun S et al (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120(8): 2715-2730.
18. Hornberg E et al (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6(4): e19059.
19. Li Y et al (2011) Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 71(6): 2108-2117.
20. Liu G et al (2013) AR variant AR(v567es) induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia 15(9): 1009-1017.
21. Chang C et al (2013) Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. doi: 10. 1038/onc. 2013. 274.
22. Siddique HR et al (2012) Androgen receptor in human health: a potential therapeutic target. Curr Drug Targets 13(14): 1907-1916.
23. Hickey TE et al (2012) Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 26(8): 1252-1267.
24. Laurentino SS et al (2013) Identification of androgen receptor variants in testis from humans and other vertebrates. Andrologia 45(3): 187-194.
25. Zhu X et al (1997) Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer. Int J Cancer 72(4): 574-580.
26. Bhasker CR et al (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10(8): 679-685.
27. Bhasker CR et al (1997) Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 7(1): 51-58.
28. McKinnon RA et al (1991) Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology 14(5): 848-856.
29. Hu DG, Mackenzie PI (2009) Estrogen receptor alpha, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17beta-estradiol in MCF-7 cells. Mol Pharmacol 76(2): 425-439.
30. Watson PA et al (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107(39): 16759-16765.
31. Gottlieb B et al (2012) The androgen receptor gene mutations database: 2012 update. Hum Mutat 33(5): 887-894.
32. Lim J, Ghadessy FJ, Yong EL (1997) A novel splice site mutation in the androgen receptor gene results in exon skipping and a non-functional truncated protein. Mol Cell Endocrinol 131(2): 205-210.
33. Hellwinkel OJ et al (1999) Complete androgen insensitivity caused by a splice donor site mutation in intron 2 of the human androgen receptor gene resulting in an exon 2-lacking transcript with premature stop-codon and reduced expression. J Steroid Biochem Mol Biol 68(1-2): 1-9.
34. Ris-Stalpers C et al (1994) Differential splicing of human androgen receptor pre-mRNA in X-linked Reifenstein syndrome, because of a deletion involving a putative branch site. Am J Hum Genet 54(4): 609-617.
35. Dehm SM, Tindall DJ (2011) Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18(5): R183-R196.
36. Tress ML et al (2007) The implications of alternative splicing in the ENCODE protein complement. Proc Natl Acad Sci U S A 104(13): 5495-5500.
37. Guo Z, Qiu Y (2011) A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int J Biol Sci 7(6): 815-822.
38. Farmer P et al (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24(29): 4660-4671.
39. Doane AS et al (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25(28): 3994-4008.
40. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7): 2557-2576.
41. Chao Y et al (1996) Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer 77(4): 635-639.
42. (2004) Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology 40(6): 1361-1369.
43. Chan SC, Li Y, Dehm SM (2012) Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 287(23): 19736-19749.
44. Zhuang YA, Goldstein AM, Weiner AM (1989) UACUAAC is the preferred branch site for mammalian mRNA splicing. Proc Natl Acad Sci U S A 86(8): 2752-2756.